Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Thall

Showing results (131-140 of 184) with videos related to

Pageof 19
Sort By:
The Prostate|September 21, 2007
Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapiesShifeng Mao, Danai D Daliani, Xuemei Wang, et al.
Cancer|January 9, 2009
A possible association between aprotinin and improved survival after radical surgery for mesotheliomaPeter H Norman, Peter F Thall, Ronaldo V Purugganan, et al.
Journal of Clinical Anesthesia|August 24, 2024
Intraoperative methadone administration for total mastectomy: A single center retrospective studyJuan P Cata, Yusuf Zaidi, Juan Jose Guerra-Londono, et al.
Blood Advances|November 10, 2020
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patientsBetül Oran, Marcos de Lima, Guillermo Garcia-Manero, et al.
The Annals of Thoracic Surgery|May 7, 2013
Visceral pleural invasion is not predictive of survival in patients with lung cancer and smaller tumor sizeElizabeth David, Peter F Thall, Neda Kalhor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2004
Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomesJanice N Cormier, Xuelin Huang, Yan Xing, et al.
Bone Marrow Transplantation|December 12, 2018
Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDSGheath Alatrash, Kelly M Kidwell, Peter F Thall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioningChristopher G Kanakry, Paul V O'Donnell, Terry Furlong, et al.
The Journal of Urology|November 18, 2008
Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancerPaul Mathew, Louis L Pisters, Christopher G Wood, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 21, 2008
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDSBorje S Andersson, Marcos de Lima, Peter F Thall, et al.
Pageof 19

Showing results (131-140 of 184) with videos related to

Sort By:
Pageof 19
The Prostate|September 21, 2007
Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapiesShifeng Mao, Danai D Daliani, Xuemei Wang, et al.
Cancer|January 9, 2009
A possible association between aprotinin and improved survival after radical surgery for mesotheliomaPeter H Norman, Peter F Thall, Ronaldo V Purugganan, et al.
Journal of Clinical Anesthesia|August 24, 2024
Intraoperative methadone administration for total mastectomy: A single center retrospective studyJuan P Cata, Yusuf Zaidi, Juan Jose Guerra-Londono, et al.
Blood Advances|November 10, 2020
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patientsBetül Oran, Marcos de Lima, Guillermo Garcia-Manero, et al.
The Annals of Thoracic Surgery|May 7, 2013
Visceral pleural invasion is not predictive of survival in patients with lung cancer and smaller tumor sizeElizabeth David, Peter F Thall, Neda Kalhor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2004
Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomesJanice N Cormier, Xuelin Huang, Yan Xing, et al.
Bone Marrow Transplantation|December 12, 2018
Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDSGheath Alatrash, Kelly M Kidwell, Peter F Thall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioningChristopher G Kanakry, Paul V O'Donnell, Terry Furlong, et al.
The Journal of Urology|November 18, 2008
Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancerPaul Mathew, Louis L Pisters, Christopher G Wood, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 21, 2008
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDSBorje S Andersson, Marcos de Lima, Peter F Thall, et al.
Pageof 19